Nexalin Technology, Inc.

NasdaqCM NXL

Nexalin Technology, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 228.18

Nexalin Technology, Inc. Price to Sales Ratio (P/S) is 228.18 on January 14, 2025, a 609.72% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Nexalin Technology, Inc. 52-week high Price to Sales Ratio (P/S) is 359.94 on December 04, 2024, which is 57.74% above the current Price to Sales Ratio (P/S).
Nexalin Technology, Inc. 52-week low Price to Sales Ratio (P/S) is 23.69 on February 12, 2024, which is -89.62% below the current Price to Sales Ratio (P/S).
Nexalin Technology, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 114.55.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqCM: NXL

Nexalin Technology, Inc.

CEO	Mr. Mark White
IPO Date	Sept. 16, 2022
Location	United States
Headquarters	1776 Yorktown
Employees	6
Sector	Health Care
Industries Pharmaceuticals Medical Instruments

Description

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia. The company was incorporated in 2021 and is headquartered in Houston, Texas.

Key trends

Past 5 years